

DIRECTORS REPORT

We are pleased to present the unaudited condensed interim financial statements of the Company for the six months ended December 31, 2021. These financial statements have been prepared in accordance with the requirements of the International Accounting Standard (IAS) 34 'Interim Financial Reporting' and the director report is prepared in accordance with section 227 of Companies Act, 2017 and Chapter XII of the Listed Companies (Code of Corporate Governance) Regulations, 2019.

COMPOSITION OF BOARD

The total number of directors are 7 as the following:

1. Male 5
2. Female 2

Sr. No.	Category	Name
1	Independent Director	1. Mr. Abdul Jaleel Shaikh 2. Ms. Farzin Khan
2	Executive Director	1. Mr. Rizwan Ahmad 2. Mr. Dr. Zameer Ul Hassan Shah
3	Non Executive Director	1. Mr. Nadeem Amjad 2. Mr. Muhammad Naeem 3. Ms. Saira Aslam

COMPARATIVE FINANCIAL RESULTS

The financial results are summarized below: -

	Three month ended		Six Month Ended	
	Dec 31, 2021	Dec 31, 2020	Dec 31, 2021	Dec 31, 2020
	(Un-audited)	(Un-audited)	(Un-audited)	(Audited)
	-----Rupees-----			
Sales- Net	2,850,278,592	1,353,420,758	4,841,231,409	2,631,575,470
Cost of sales	(2,445,219,540)	(1,106,194,522)	(4,139,830,800)	(2,221,330,714)
Gross profit	405,059,052	247,226,236	701,400,609	410,244,756
Administrative expenses	(43,832,345)	(26,299,360)	(203,720,687)	(60,158,882)
Selling expenses	(28,940,392)	(31,575,386)	(54,359,913)	(63,371,329)
Financial Charges	(25,925,319)	(7,523,834)	(34,127,097)	(16,576,536)
Other income/(Loss)	58,402,733	(801,803)	89,254,858	1,536,500
Other Expenses	(24,596,263)	(10,449,497)	(33,360,465)	(18,683,223)
	(64,891,588)	(76,649,880)	(236,313,306)	(157,253,470)
Profit before Taxation	340,167,464	170,576,356	465,087,303	252,991,286
Taxation	(78,469,740)	(68,479,674)	(122,032,906)	(84,456,608)
Profit for the period	261,697,724	102,096,682	343,054,397	168,534,678
Earnings per share (EPS)		Restated		Restated
- Basic and Diluted	1.11	1.55	1.52	2.56

FUTURE PROSPECTS

The following expansion is underway:

API segment: In the wake of the COVID-19 pandemic, demand for Paracetamol witnessed a surge. Moreover, health awareness and health spending has also risen. Hence, CPHL intends to expand their existing capacity of 3,600 tons per annum of Paracetamol to 6,000 tons per annum. Further to this, CPHL plans to add new APIs to its existing product line, i.e. (i) Ascorbic Acid, (ii) Chloroquine Phosphate, and (iii) Hydroxychloroquine Sulfate; subsequently, these will also add formulation products of the same to the Company's portfolio.


Particulars	Capacity (Tons) p.a
Ascorbic Acid	1200
Chloroquine Phosphate	50
Hydroxychloroquine Sulfate	50

In the Formulation Segment, the Company intends to build three manufacturing facilities taking total capacity to 200,000 vials/injectable per day, dry powder/suspension 60,000 bottles per day, capsules 4,200,000 per day, and tablets 4,500,000 per day. These include dedicated lines for (i) Penicillin 36, (ii) Cephalosporin and (iii) Psychotropic & Narcotics drugs³⁷.

As per guidelines of DRAP, in API manufacturing a separate dedicated line is required to eliminate any chances of cross contamination. CPHL's in-house engineering team shall be responsible for civil, electrical and mechanical work for both API and formulation. Further, they will also be responsible for procurement and installation of machinery for both the API.

Ministry of National Health Services has approved the layout plan of Carbapenem facility. Further, directors also decided to increase the number of beds of the hospital from 50 to 200 which will also improve revenue and profitability of the Company.

For and on behalf of the of Board



(Rizwan Ahmad)
Chief Executive Officer

Lahore
Dated: February 21, 2021



Aslam Malik & Co.
Chartered Accountants
building better together (Est.1971)

www.aslammalik.com
info@aslammalik.com
aslammalik@brain.net.pk
+92-42-35858693-35858694
+92-42-35856819
+92-42-35856019

INDEPENDENT AUDITOR'S REVIEW REPORT

To the members of CITI PHARMA LIMITED Report on Review of Interim Financial Statements

Introduction

We have reviewed the accompanying condensed interim statement of financial position of **CITI PHARMA LIMITED** as at December 31, 2021 and the related condensed interim statement of profit or loss, the condensed interim statement of other comprehensive income, condensed interim statement of changes in equity, and condensed interim statement of cash flows, and notes to the financial statements for the six-months period then ended (here-in-after referred to as the "condensed interim financial statements"). Management is responsible for the preparation and presentation of these interim financial statements in accordance with accounting and reporting standards as applicable in Pakistan for interim financial reporting. Our responsibility is to express a conclusion on these condensed interim financial statements based on our review.

The figures of the condensed interim statement of profit or loss, the condensed interim statement of other comprehensive income for the quarters ended December 31, 2021 and December 31, 2020 have not been reviewed, as we are required to review only the cumulative figures for the six months ended December 31, 2021.

Scope of Review

We conducted our review in accordance with International Standard on Review Engagements 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity". A review of condensed interim financial statements consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Conclusion

Based on our review, nothing has come to our attention that causes us to believe that the accompanying condensed interim financial statements are not prepared, in all material respects, in accordance with the accounting and reporting standards as applicable in Pakistan for interim financial reporting.

The engagement partner on the review resulting in this independent auditor's report is **Hafiz Muhammad Ahmad Saleem-ACA**.

Aslam Malik

Aslam Malik & Co.
Chartered Accountants



Place: Lahore
Date:

21 FEB 2022

UDIN: RR2021101481JDoI7d4C

📍 **Lahore Head Office:** Suite # 18-19 FF Floor, Central Plaza, Civic Centre, New Garden Town, Lahore-Pakistan.

📍 **Islamabad Office:** House # 726, Street 34, Margalla Town, off Murree Road, Islamabad. Phone : +92-51-2374282-3

📍 **Quetta Office:** 1st Floor, Haji Fateh Khan Center, Adalat Road, Quetta Ph: +92-81-2823837

CITI PHARMA LIMITED
CONDENSED INTERIM STATEMENT OF FINANCIAL POSITION
AS AT DECEMBER 31, 2021

December 31, 2021
(Un-audited)

June 30, 2021
(Audited)

Note -----Rupees-----

EQUITY AND LIABILITIES

SHARE CAPITAL AND RESERVES

Authorised Capital:

300,000,000 Ordinary shares of Rs. 10/- each

3,000,000,000 **3,000,000,000**

Issued, subscribed and Paid up Capital:

228,461,200 (June 2021: 135,000,000) Ordinary shares of Rs. 10/- each

Share Deposit Money

Share Premium

Revenue reserves-Unappropriated profits

Revaluation Surplus on Land

2,284,612,000	1,350,000,000
-	2,326,144,000
1,391,532,000	-
412,122,981	380,606,584
309,294,525	309,294,525

4,397,561,506 **4,366,045,109**

NON CURRENT LIABILITIES

Long Term Financing - Secured

Deferred Liabilities

Deferred Grant

Lease Liabilities

314,232,587	189,157,811
85,784,614	91,419,343
44,653,681	9,273,278
8,034,964	7,755,356

452,705,846 **297,605,788**

CURRENT LIABILITIES

Trade and other payables

Director's Loan

Payable to Investors Against Excess Proceeds

Short Term Borrowings-Secured

Current Portion of Long Term Liabilities-Secured

Dividend Payable

Accrued Mark Up

Provision for taxation

1,706,667,163	1,051,670,069
12,200,000	12,200,000
-	521,384,357
285,617,262	-
164,715,711	122,936,714
4,410,652	-
11,528,807	451,598
125,474,159	126,869,102

2,310,613,753 **1,835,511,840**

Contingencies and Commitments

-	-
---	---

TOTAL EQUITY AND LIABILITIES

7,160,881,105 **6,499,162,737**

ASSETS

NON CURRENT ASSETS

Property, plant and equipment

Work in Progress

Long term security deposits

Long Term Investments

1,706,399,739	1,734,765,860
64,510,862	-
9,675,350	8,613,950
350,790,900	254,540,900

2,131,376,851 **1,997,920,710**

CURRENT ASSETS

Stock in Trade

Trade Debts- Unsecured

Short Term Investments (TDRs)

Advances deposits, prepayments and other receivables

Cash and bank balance

1,589,691,954	778,194,441
596,384,296	444,545,802
2,558,979,484	-
244,367,869	204,077,281
40,080,651	3,074,424,503

5,029,504,254 **4,501,242,027**

TOTAL ASSETS

7,160,881,105 **6,499,162,737**

Auditor's report is annexed.

The annexed notes form an integral part of these condensed interim financial statements.



Chief Executive



Chief Financial Officer




Director

CITI PHARMA LIMITED
CONDENSED INTERIM STATEMENT OF PROFIT OR LOSS (UN-AUDITED)
FOR THE HALF YEAR ENDED DECEMBER 31, 2021

	Three month ended		Six Month Ended	
	December 31, 2021 (Un-audited)	December 31, 2020 (Un-audited)	December 31, 2021 (Un-audited)	December 31, 2020 (Audited)
Notes	-----Rupees-----			
Sales- Net	2,850,278,592	1,353,420,758	4,841,231,409	2,631,575,470
Cost of sales	(2,445,219,540)	(1,106,194,522)	(4,139,830,800)	(2,221,330,714)
Gross profit	405,059,052	247,226,236	701,400,609	410,244,756
Administrative expenses	43,832,345	26,299,360	203,720,687	60,158,882
Selling expenses	28,940,392	31,575,386	54,359,913	63,371,329
	(72,772,737)	(57,874,746)	(258,080,600)	(123,530,211)
Operating Profit	332,286,314	189,351,490	443,320,008	286,714,545
Financial Charges	(25,925,319)	(7,523,834)	(34,127,097)	(16,576,536)
	306,360,995	181,827,656	409,192,911	270,138,009
Other income/(Loss)	58,402,733	(801,803)	89,254,858	1,536,500
	364,763,727	181,025,853	498,447,768	271,674,509
Other Expenses	(24,596,263)	(10,449,497)	(33,360,465)	(18,683,223)
Profit before Taxation	340,167,464	170,576,356	465,087,303	252,991,286
Taxation	(78,469,740)	(68,479,674)	(122,032,906)	(84,456,608)
Profit for the period	261,697,724	102,096,682	343,054,397	168,534,678
Earnings per share (EPS)		Restated		Restated
- Basic and Diluted	1.11	1.55	1.52	2.56

The annexed notes form an integral part of these condensed interim financial statements.


Chief Executive


Chief Financial Officer


Director

CITI PHARMA LIMITED
 CONDENSED INTERIM STATEMENT OF COMPREHENSIVE INCOME (UN-AUDITED)
 FOR THE HALF YEAR ENDED DECEMBER 31, 2021

Note	Three month ended		Six Month Ended	
	December 31, 2021 (Un-audited)	December 31, 2020 (Audited)	December 31, 2021 (Un-audited)	December 31, 2020 (Audited)
	-----Rupees-----			
Profit for the period	261,697,724	102,096,682	343,054,397	168,534,678
Other comprehensive income for the period	-	-	-	-
Item that will not be reclassified subsequently to Profit or Loss				
Revaluation Surplus on Land	-	-	-	709,294,525
Total comprehensive income for the Period	261,697,724	102,096,682	343,054,397	877,829,203

The annexed notes form an integral part of these condensed interim financial statements.



Chief Executive



Chief Financial Officer



Director

CITI PHARMA LIMITED
CONDENSED INTERIM STATEMENT OF CASH FLOWS (UN-AUDITED)
FOR THE HALF YEAR ENDED DECEMBER 31, 2021

December 31, 2021 **December 31, 2020**
(Un-audited) **(Audited)**
-----Rupees-----

CASH FLOW FROM OPEARTING ACTIVITIES

Profit Before Taxation for the period

Adjustments For Non- Cash Items And Other Line Items:

Depreciation	38,726,998	28,157,335
Financial Charges	34,127,097	16,576,536
Accrued Interest Income	(34,316,164)	-
Amortisation of Deferred Grant	(5,952,716)	(288,030)
Gratuity Expense	2,270,531	-
Worker's Profit Participation Fund	24,922,388	13,583,725
Worker's Welfare Fund	8,438,077	5,099,498
	68,216,211	63,129,064

Profit/ (Loss) before working capital changes

533,303,513 **316,120,350**

Effect of working capital changes

Advances, Deposits And Prepayments	48,542,306	43,395,806
Trade Debts	(151,838,494)	21,040,450
Stock In Trade	(811,497,513)	(561,715,251)
Trade And Other Payables	656,907,338	180,455,169
	(257,886,364)	(316,823,825)

Financial Charges Paid

(23,049,889) (15,533,028)

Income Tax Paid

(185,849,838) (74,032,268)

Worker's Profit Participation Fund

(26,750,855) (11,100,883)

Worker's Welfare Fund

(8,519,855) (4,027,239)

(244,170,437) (104,693,418)

Net cash flow from operating activities

A **31,246,713** **(105,396,893)**

CASH FLOW FROM INVESTING ACTIVITIES

Purchase Of Property, Plant & Equipment	(6,115,276)	(47,724,000)
Paid for Capital Work in Progress	(64,510,862)	-
Paid for Long Term Security Deposits	(1,061,400)	-
Long Term Investment	(96,250,000)	-
Short Term Investments	(2,558,979,484)	-
	(2,726,917,022)	(47,724,000)

Net cash flow from investing activities

B **(2,726,917,022)** **(47,724,000)**

CASH FLOW FROM FINANCING ACTIVITIES

Proceeds less repayment of Long Term Financing	205,686,353	67,729,914
Paid to Investors Against Excess Proceeds	(521,384,357)	-
Lease Rentals Paid	(1,465,453)	(4,323,104)
Dividend Paid	(307,127,348)	-
Short Term Borrowings	285,617,262	94,554,795
	(338,673,543)	157,961,605

Net Cash flow From Investing Activities

C **(338,673,543)** **157,961,605**

Net Increase/ (decrease) in cash and cash equivalents

A+B+C **(3,034,343,852)** **4,840,712**

Cash and cash equivalents at beginning of the period

3,074,424,503 89,444,317

Cash and cash equivalents at end of the period

40,080,651 **94,285,029**

Cash and cash equivalents comprise of:

Cash in hand	352,424	214,356
Cash at bank	39,728,227	94,070,673
	40,080,651	94,285,029

The annexed notes form an integral part of these condensed interim financial statements.


Chief Executive


Chief Financial Officer


Director

CITI PHARMA LIMITED
 CONDENSED INTERIM STATEMENT OF CHANGES IN EQUITY (UN-AUDITED)
 FOR THE YEAR ENDED DECEMBER 31, 2021

PARTICULARS	SHARE CAPITAL	SHARE DEPOSIT MONEY	SHARE PREMIUM	REVENUE RESERVES	REVALUATION SURPLUS	TOTAL
----- Rupees -----						
Balance as at June 30, 2020- (Audited)	450,000,000	-	-	528,308,204	-	978,308,204
Total Comprehensive Income for the six months						
Profit for the period	-	-	-	168,534,678	-	168,534,678
Other comprehensive income	-	-	-	-	709,294,525	709,294,525
	-	-	-	168,534,678	709,294,525	877,829,203
Balance as at December 31, 2020- (Un-audited)	450,000,000	-	-	696,842,882	709,294,525	1,856,137,407
Balance as at June 30, 2021- (Audited)	1,350,000,000	2,326,144,000	-	380,606,584	309,294,525	4,366,045,109
Total Comprehensive Income for the six months						
Profit for the period	-	-	-	343,054,397	-	343,054,397
Other comprehensive income	-	-	-	-	-	-
	-	-	-	343,054,397	-	343,054,397
72,692,000 shares issued to general public at a strike price of Rs. 32 each	726,920,000	(2,326,144,000)	1,599,224,000	-	-	-
Final Dividend Paid for the year ended June 2021 @ 15%	-	-	-	(311,538,000)	-	(311,538,000)
Issuance of Bonus Shares at the rate of 10% for every one share held	207,692,000	-	(207,692,000)	-	-	-
Balance as at December 31, 2021- (Un-audited)	2,284,612,000	-	1,391,532,000	412,122,981	309,294,525	4,397,561,506

The annexed notes form an integral part of these condensed interim financial statements.



Chief Executive



Chief Financial Officer



Director

Notes	December 31, 2021 (Un-audited)	June 30, 2021 (Audited)
	-----Rupees-----	
4 SHARES CAPITAL		
Authorized share capital	3,000,000,000	3,000,000,000
300,000,000 Ordinary shares of Rs. 10/- each		
Issued, subscribed and paid up capital		
Opening Balance		
45,000,000 Ordinary shares of Rs. 10 each, fully paid in cash	450,000,000	450,000,000
90,000,000 Ordinary Share of Rs. 10 each issued as fully paid Bonus shares	900,000,000	-
Movement During the period / year		
72,692,000 ordinary shares issued through IPO at a premium of Rs. 22	726,920,000	-
20,769,200 (June 2021: 90,000,000) Ordinary Share of Rs. 10 each issued as fully paid Bonus shares	207,692,000	900,000,000
Closing Balance		
45,000,000 (June 2021: 4,500,000) Ordinary shares of Rs. 10 (2020: 100) each, fully paid in cash	1,176,920,000	450,000,000
90,000,000 Ordinary Share of Rs. 10 each issued as fully paid Bonus shares	1,107,692,000	900,000,000
228,461,200 (June 2021: 135,000,000) Ordinary shares of Rs. 10/- each	2,284,612,000	1,350,000,000
5 LONG TERM FINANCING - SECURED		
Long term loan from Pak Brunei Investment Company	5.1 108,333,344	139,583,342
Term finance against purchase of machinery from Bank Al-Habib Limited	5.2 12,456,800	32,393,013
Term Loan For Salary & Wages Under SBP Refinance Scheme from Bank Al-Habib Limited	5.3 33,880,102	59,108,483
Finance of Machinery in SBP (TERF) from Bank Al-Habib Limited	5.4 71,408,910	84,642,658
Term Finance under RFCC from Bank of Punjab	5.5 300,000,000	-
	526,079,156	315,727,496
Deferred Grant	(66,699,833)	(17,863,734)
Current Portion shown under current liabilities	(145,146,736)	(108,705,951)
	314,232,587	189,157,811
5.1 This loan is obtained from Pak Brunei Investment company which carries mark up of three months KIBOR + 250 bps and is repayable in 48 installments. The arrangement is secured against Fixed Assets and Personal guarantees of all directors of the company.		
5.2 Term Finance Facility is obtained from the Bank Al Habib Limited with mark up of three months KIBOR + 225 bps and is repayable in 48 installments.		
5.3 The Company has obtained long term loans from Bank Al Habib Limited amounting Rs. 61.27 million for financing its salaries and wages under SBP Refinance Scheme for payment of wages and salaries, earmarked from running finance limit, which is secured against first Joint Pari Passu Hypothecation charge over stock and book debts. The rate of markup on these loans are at 3% per annum. These loans are for two and half years and are repayable in eight equal quarterly instalments.		
5.4 The Company has also obtained long term loans of Rs. 84.64 million for financing import of plant and machinery from Bank Al-Habib Limited, which is secured against first Joint Pari Passu Hypothecation charge over stock and book debts. The rate of markup on these loans are at 5% per annum which include 4% BAML share and 1% SBP share. These loans are for four years and are repayable in fifteen equal quarterly instalments under SBP TERF scheme including three month grace period from the date of disbursement and mark up to be recoverable on quarterly basis		
5.5 In addition to the above, the company has also obtained TF under RFCC for SBP financing civil work of building & procurement of medical equipment and machinery for setting up a new hospital comprising of 50 beds from Bank of Punjab at the rate of SBP Refinance rate + 3% p.a while SBP Rate of Refinance will be 0% or as per time to time. Principal is repayable in equal 18 quarterly installments with grace period of six months while mark up is payable in 20 installment on quarterly basis.		
6 DEFERRED GRANT		
As at 01 July	15,131,695	570,828
Received during the year	51,568,138	17,863,734
Amortization	(5,952,716)	(3,302,867)
	60,747,117	15,131,695
Current portion	(16,093,436)	(5,858,417)
As at 30th June	44,653,681	9,273,278
7 LEASE LIABILITIES		
The amount of future minimum lease payments along with their present value and the period during which they fall due are as under:		
Not later than one year	4,607,988	3,802,816
Later than one year but not later than five years	9,166,844	8,825,767
	13,774,832	12,628,583
Less: Finance charge	(2,264,329)	(1,883,332)
	11,510,503	10,745,251
Less: Current maturity of long term obligation	(3,475,539)	(2,989,895)
	8,034,964	7,755,356
Payable within one year	3,475,539	2,989,895
Payable after one year	8,034,964	7,755,356
	11,510,503	10,745,251

7.1 The Company entered into lease agreements with financial institutions to acquire vehicles. The liabilities under the lease agreements are payable in equal monthly installments and are subject to finance charges at the rates ranging from 6 months KIBOR + 2.5% per annum (June 30, 2021 : 6 months KIBOR + 2.5% per annum). The lease liabilities are secured against security deposits, post dated cheques, and also secured against financed vehicles.

8 CONTINGENCIES AND COMMITMENTS

There has been no material change in the status of contingencies and commitments disclosed in note 15 to the Company's financial statements for the year ended June 30, 2021.

9 PROPERTY PLANT & EQUIPMENT

	Notes	December 31, 2021 Rupees	June 30, 2021 Rupees
Operating fixed assets	9.1	1,686,217,939	1,714,845,610
Right of Used Assets	9.2	20,181,800	19,920,250
		1,706,399,739	1,734,765,860
9.1 Operating Fixed Assets			
Opening Written down value as at July 01, 2021		1,714,845,610	789,558,074
Addition during the period/year	9.1.1	6,115,276	276,701,531
Disposal during the period/year		-	-
Revaluation Surplus on Land		-	709,294,525
		6,115,276	985,996,056
Depreciation charged for the period/ year		(34,742,948)	(60,708,520)
Closing written down value		1,686,217,939	1,714,845,610
9.1.1 Details of additions during the period/year as follows:			
Plant & Machinery		-	270,508,851
Vehicles		-	153,000
Office Equipments		1,018,250	1,468,670
Books		-	30,000
Furniture and Fixtures		4,071,035	2,496,435
Computers		1,025,991	2,044,575
		6,115,276	276,701,531
9.2 Right of Used Assets			
Opening Balance		19,920,250	24,900,313
Addition during the period/year		4,245,600	-
Depreciation charged during the period/year		(3,984,050)	(4,980,063)
		20,181,800	19,920,250

10 OTHER INCOME

Other Income represents Profits on Savings accounts, Profit on Term Deposits Receipts, dividend income, amortisation of grant income and gain on investment in shares

11 TRANSACTION WITH RELATED PARTIES

The Related parties comprise principal shareholders and their affiliates, directors, companies with common directorship and key management personnel. Details of transactions and balances at period end with related parties, other than those which have been disclosed elsewhere in these condensed interim financial statements, are as follows:

			Half year ended	
			December 31, 2021	December 31, 2020
			-----Rupees-----	
11.1 Transaction for the period				
	Nature	Relationship		
	Salary	CEO	4,200,000	1,625,000
	Salary	Directors	5,700,000	1,300,000
	Dividend Paid	CEO	60,750,000	-
	Dividend Paid	Directors	101,249,982	-
11.2 Balance as at period/ year end				
	Name of Related Party	Nature	Relationship	
-	Yaqeen Developers Limited	Investment	Associated Company	254,540,900
-	Short Term Loan from directors	Loan Obtained	Directors	12,200,000
				197,975,993
				17,200,000

12 UTILIZATION OF PROCEEDS FROM INITIAL PUBLIC OFFERING

The principal purpose of the issue was to increase the capacity in both segment of Active Pharmaceutical Ingredients (API) and Formulation and to set up a state of the art, 50 bed hospital facility in Gulberg III, Lahore.

Estimated break-up of utilization of the IPO proceeds is mentioned below:

Description	Funds Required (Rupees)	Allocation (%)	Actual Expenditure (Rupees)	Excess/ (Less) Incurred (Rupees)
API Segment				
Civil Works	150,000,000	7%	35,563,895	(114,436,105)
Procurement of Plant and Machinery	405,194,500	20%	24,715,343	(380,479,157)
	555,194,500	27.28%	60,279,238	(494,915,262)
Formulation Segment				
Civil Works	250,000,000	12%	95,104,023	(154,895,977)
Procurement of Plant and Machinery	307,630,000	15%	179,636,452	(127,993,548)
	557,630,000	27.40%	274,740,475	(282,889,525)
Hospital Facility				
Civil Work of Hospital Building (incl. Electrical and Mechanical work)	668,000,000	33%	-	(668,000,000)
Plant and Machinery for Hospital	254,551,500	13%	-	(254,551,500)
	922,551,500	45.33%	-	(922,551,500)
Utilization of Excess Proceeds				
Repayment of Borrowings	54,197,497	19%	54,197,497	-
Working Capital Requirement	108,902,639	37%	108,902,639	-
IPO Expenses	127,667,864	44%	127,667,864	-
	290,768,000	100%	290,768,000	-

13 FINANCIAL RISK MANAGEMENT AND FAIR VALUE DISCLOSURES

13.1 Financial risk management information and disclosures

These condensed interim financial statements do not include all financial risk management information and disclosures which are required in the annual financial statements and should be read in conjunction with the Company's annual financial statements for the year ended June 30, 2021. There have been no change in any risk management policies since the year end.

13.2 Fair Value of Financial Instrument

IFRS - 13 Fair Value Measurement establishes a single source of guidance under the IFRS for the fair value measurements and disclosures about the fair value measurement where such measurements are required as permitted by other IFRSs. It defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an ordinary transaction between market participants at the measurement date (i.e. an exit price).

The table below analyses financial instruments carried at fair value by valuation method. The different levels have been defined as follows:

Level 1: quoted prices in active markets for identical assets or liabilities;

Level 2: those involving inputs other than quoted prices included in level 1 that are observable for the asset or liability, either directly (as prices) or indirectly (derived from prices); and

Level 3: those with inputs for the asset or liability that are not based on observable market data (unobservable inputs).

	Level 1	Level 2	Level 3	Total
Financial assets - fair value through profit or loss	-	-	-	-
- Short-term investment (shares of PSX)	129,461,090	-	-	129,461,090

14 EVENTS AFTER THE REPORTING PERIOD

There are no other significant events after the reporting period which may require adjustment of and/or disclosure in these financial statements.

15 DATE OF AUTHORIZATION FOR ISSUE

These condensed interim financial statements were authorized for issue on **February 21, 2022** by the board of directors of the company.


16 GENERAL

The figures have been rounded off to the nearest rupees.

Corresponding figures have been rearranged, and reclassified, where necessary, for better presentation and disclosure.



Chief Executive



Chief Financial Officer



Director